MNPR
Monopar Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$117.56
−0.84%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−35.4x
Market Cap
$789.08M
MomentumView details →
1D Return
−0.84%
YTD Return
+80.77%
RSI (14)
57.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−35.4x
Market Cap
$789.08M
RSI (14)
57.2
MomentumView details →
1D Return
−0.84%
YTD Return
+80.77%
SummaryUpdated Jun 1, 2026
Monopar Therapeutics Inc. (NASDAQ:MNPR) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Wilmette, Illinois. The company went public in December 2019 and focuses on developing innovative therapeutic treatments for cancer patients. As a clinical-stage biotechnology firm, Monopar does not yet generate revenue from product sales but instead operates through research and development activities funded by investor capital and potential partnerships.
Similar companies
Latest newsMore news →
Kim R. Tsuchimoto, a director at Monopar Therapeutics, sold 4,090 shares of common stock on August 26, 2026, for a total value of $455,566, and exercised options to acquire the same number of shares on the same day.7d agoMonopar Therapeutics reported a net loss of $5.3 million, or $0.62 per share, for Q2 2026, compared to a net loss of $2.5 million, or $0.35 per share, in Q2 2025.24d ago